| 國家衛生研究院 |
2022-12 |
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
|
Geyer, CE, Jr.;Garber, JE;Gelber, RD;Yothers, G;Taboada, M;Ross, L;Rastogi, P;Cui, K;Arahmani, A;Aktan, G;Armstrong, AC;Arnedos, M;Balmaña, J;Bergh, J;Bliss, J;Delaloge, S;Domchek, SM;Eisen, A;Elsafy, F;Fein, LE;Fielding, A;Ford, JM;Friedman, S;Gelmon, KA;Gianni, L;Gnant, M;Hollingsworth, SJ;Im, SA;Jager, A;Jóhannsson, Ó;Lakhani, SR;Janni, W;Linderholm, B;Liu, TW;Loman, N;Korde, L;Loibl, S;Lucas, PC;Marmé, F;Martinez de Dueñas, E;McConnell, R;Phillips, KA;Piccart, M;Rossi, G;Schmutzler, R;Senkus, E;Shao, Z;Sharma, P;Singer, CF;Španić, T;Stickeler, E;Toi, M;Traina, TA;Viale, G;Zoppoli, G;Park, YH;Yerushalmi, R;Yang, H;Pang, D;Jung, KH;Mailliez, A;Fan, Z;Tennevet, I;Zhang, J;Nagy, T;Sonke, GS;Sun, Q;Parton, M;Colleoni, MA;Schmidt, M;Brufsky, AM;Razaq, W;Kaufman, B;Cameron, D;Campbell, C;Tutt, ANJ |
